We serve Chemical Name:2-Methylhydroquinone CAS:95-71-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-Methylhydroquinone
CAS.NO:95-71-6
Synonyms:2-Methylbenzene-1,4-diol;2-Methyl-1,4-benzenediol;MFCD00002345;2-Methylhydroquinone;EINECS 202-443-7;1,4-Benzenediol, 2-methyl-;2041489;QR DQ B1
Molecular Formula:C7H8O2
Molecular Weight:124.137
HS Code:29072900
Physical and Chemical Properties:
Melting point:125-128ºC
Boiling point:277.8±20.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.595
PSA:40.46000
Exact Mass:124.052429
LogP:1.10
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 2811
Packing Group:III
Contact us for information like 2-Methylbenzene-1,4-diol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,QR DQ B1 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Methylhydroquinone Use and application,1,4-Benzenediol, 2-methyl- technical grade,usp/ep/jp grade.
Related News: Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML). 2-Methylhydroquinone manufacturer Our previous work with Retrogenix validated their technology as a uniquely powerful approach for antibody target deconvolution, and we look forward to working with Retrogenix to enhance our growing pipeline of antibody candidates.�� 2-Methylhydroquinone supplier Inceptua has global operations with local offices across Europe, USA, and Asia 2-Methylhydroquinone vendor Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML). 2-Methylhydroquinone factory Catalent��s clinical supply network includes nine cGMP-certified clinical packaging facilities across North America, Europe and Asia, and more than 50 strategically-located depots around the world, providing local and regional options for clinical storage, distribution, expiry update and relabeling services, and clinical returns management.
